Danaher Stock Drops Despite Strong Earnings | Business and Finance News

Danaher’s stock plunged 12% after a solid earnings report, fueled by a surprise biotech sales slowdown — despite beating estimates and raising full-year guidance thanks to its Masimo acquisition. The dip stems from delayed consumable shipments to big pharma clients, pushing key revenue into next year. Analysts debate if this is a temporary timing glitch or a red flag — but long-term investors may see it as a buying opportunity, as the market overreacts to minor growth tweaks in a volatile segment. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/051326812253f471